Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.

Jacquet E, Lardy-Cléaud A, Pistilli B, Franck S, Cottu P, Delaloge S, Debled M, Vanlemmens L, Leheurteur M, Guizard AV, Laborde L, Uwer L, Jacot W, Berchery D, Desmoulins I, Ferrero JM, Perrocheau G, Courtinard C, Brain E, Chabaud S, Robain M, Bachelot T.

Eur J Cancer. 2018 Apr 11;95:93-101. doi: 10.1016/j.ejca.2018.03.013. [Epub ahead of print]

PMID:
29655061
2.

Exosomes Induce Fibroblast Differentiation into Cancer-associated Fibroblasts through TGFβ Signaling.

R Goulet C, Bernard G, Tremblay S, Chabaud S, Bolduc S, Pouliot F.

Mol Cancer Res. 2018 Apr 10. pii: molcanres.0784.2017. doi: 10.1158/1541-7786.MCR-17-0784. [Epub ahead of print]

PMID:
29636362
3.

Efficacy and Tolerance of Lidocaine 5% Patches in Neuropathic Pain and Pain Related to Vaso-occlusive Sickle Cell Crises in Children: A Prospective Multicenter Clinical Study.

Rousseau V, Morelle M, Arriuberge C, Darnis S, Chabaud S, Launay V, Thouvenin S, Roumenoff-Turcant F, Metzger S, Tourniaire B, Marec-Berard P.

Pain Pract. 2017 Dec 20. doi: 10.1111/papr.12674. [Epub ahead of print]

PMID:
29266772
4.

Tissue-engineered human 3D model of bladder cancer for invasion study and drug discovery.

Ringuette Goulet C, Bernard G, Chabaud S, Couture A, Langlois A, Neveu B, Pouliot F, Bolduc S.

Biomaterials. 2017 Nov;145:233-241. doi: 10.1016/j.biomaterials.2017.08.041. Epub 2017 Aug 29.

PMID:
28888113
5.

Optimizing drug development in oncology by clinical trial simulation: Why and how?

Gal J, Milano G, Ferrero JM, Saâda-Bouzid E, Viotti J, Chabaud S, Gougis P, Le Tourneau C, Schiappa R, Paquet A, Chamorey E.

Brief Bioinform. 2017 May 29. doi: 10.1093/bib/bbx055. [Epub ahead of print]

PMID:
28575140
6.

ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.

Trédan O, Ménétrier-Caux C, Ray-Coquard I, Garin G, Cropet C, Verronèse E, Bachelot T, Rebattu P, E Heudel P, Cassier P, Chabaud S, Croughs T, Dupont P, C Cadore A, Clapisson G, Delgado A, Bardin-Dit-Courageot C, Rigal C, N'Kodia A, Gilles-Afchain L, Morre M, Pérol D, Blay JY, Caux C.

Ann Oncol. 2018 Feb 1;29(2):523. doi: 10.1093/annonc/mdx058. No abstract available.

PMID:
28368453
7.

Seeking the environmental source of Leptospirosis reveals durable bacterial viability in river soils.

Thibeaux R, Geroult S, Benezech C, Chabaud S, Soupé-Gilbert ME, Girault D, Bierque E, Goarant C.

PLoS Negl Trop Dis. 2017 Feb 27;11(2):e0005414. doi: 10.1371/journal.pntd.0005414. eCollection 2017 Feb.

8.

Urothelial cell expansion and differentiation are improved by exposure to hypoxia.

Chabaud S, Saba I, Baratange C, Boiroux B, Leclerc M, Rousseau A, Bouhout S, Bolduc S.

J Tissue Eng Regen Med. 2017 Nov;11(11):3090-3099. doi: 10.1002/term.2212. Epub 2017 Feb 3.

PMID:
28156053
9.

Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patients.

Eymard N, Volpert V, Kurbatova P, Volpert V, Bessonov N, Ogungbenro K, Aarons L, Janiaud P, Nony P, Bajard A, Chabaud S, Bertrand Y, Kassaï B, Cornu C, Nony P; CRESim project group.

Math Med Biol. 2018 Mar 14;35(1):25-47. doi: 10.1093/imammb/dqw019.

PMID:
28082512
10.

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival.

Rochefort P, Chabaud S, Pierga JY, Tredan O, Brain E, Bidard FC, Schiffler C, Polena H, Khalil-Mgharbel A, Vilgrain I, Bachelot T.

Br J Cancer. 2017 Jan;116(3):356-361. doi: 10.1038/bjc.2016.427. Epub 2017 Jan 5.

11.

Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Update of the Long-Term Survival Results of the GETUG-01 Randomized Study.

Pommier P, Chabaud S, Lagrange JL, Richaud P, Le Prise E, Wagner JP, Azria D, Beckendorf V, Suchaud JP, Bernier V, Perol D, Carrie C.

Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):759-769. doi: 10.1016/j.ijrobp.2016.06.2455.

PMID:
27788949
12.

How to Deal with Interval-Censored Data Practically while Assessing the Progression-Free Survival: A Step-by-Step Guide Using SAS and R Software.

Dugué AE, Pulido M, Chabaud S, Belin L, Gal J.

Clin Cancer Res. 2016 Dec 1;22(23):5629-5635. Epub 2016 Sep 23.

13.

Pre-radiation chemotherapy improves survival in pediatric diffuse intrinsic pontine gliomas.

Gokce-Samar Z, Beuriat PA, Faure-Conter C, Carrie C, Chabaud S, Claude L, Di Rocco F, Mottolese C, Szathmari A, Chabert C, Frappaz D.

Childs Nerv Syst. 2016 Aug;32(8):1415-23. doi: 10.1007/s00381-016-3153-8. Epub 2016 Jul 5.

PMID:
27379495
14.

Origin of Serum Affects Quality of Engineered Tissues Produced by the Self-Assembly Approach.

Chabaud S, Simard M, Gendreau I, Pouliot R, Bolduc S.

Scientifica (Cairo). 2016;2016:3825645. doi: 10.1155/2016/3825645. Epub 2016 May 16.

15.

Prognostic Value of Vascular Invasion in Pediatric Osteosarcomas.

Benezech S, Chabaud S, Chambon F, Dijoud F, Chotel F, Marec-Berard P.

Pathol Oncol Res. 2016 Oct;22(4):847-52. doi: 10.1007/s12253-016-0074-5. Epub 2016 May 26.

PMID:
27230613
16.

Production of a Self-Aligned Scaffold, Free of Exogenous Material, from Dermal Fibroblasts Using the Self-Assembly Technique.

Chabaud S, Bolduc S.

Dermatol Res Pract. 2016;2016:5397319. doi: 10.1155/2016/5397319. Epub 2016 Mar 9.

17.

The dynamics of gene expression changes in a mouse model of oral tumorigenesis may help refine prevention and treatment strategies in patients with oral cancer.

Foy JP, Tortereau A, Caulin C, Le Texier V, Lavergne E, Thomas E, Chabaud S, Perol D, Lachuer J, Lang W, Hong WK, Goudot P, Lippman SM, Bertolus C, Saintigny P.

Oncotarget. 2016 Jun 14;7(24):35932-35945. doi: 10.18632/oncotarget.8321.

18.

Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.

Patrikidou A, Domont J, Chabaud S, Ray-Coquard I, Coindre JM, Bui-Nguyen B, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Pérol D, Emile JF, Blay JY, Le Cesne A; French Sarcoma Group.

Eur J Cancer. 2016 Jan;52:173-80. doi: 10.1016/j.ejca.2015.10.069. Epub 2015 Dec 11.

PMID:
26687836
19.

Demonstration of the direct impact of ketamine on urothelium using a tissue engineered bladder model.

Bureau M, Pelletier J, Rousseau A, Bernard G, Chabaud S, Bolduc S.

Can Urol Assoc J. 2015 Sep-Oct;9(9-10):E613-7. doi: 10.5489/cuaj.2899. Epub 2015 Sep 9.

20.

An in silico approach helped to identify the best experimental design, population, and outcome for future randomized clinical trials.

Bajard A, Chabaud S, Cornu C, Castellan AC, Malik S, Kurbatova P, Volpert V, Eymard N, Kassai B, Nony P; CRESim & Epi-CRESim study groups.

J Clin Epidemiol. 2016 Jan;69:125-36. doi: 10.1016/j.jclinepi.2015.06.024. Epub 2015 Jul 15.

PMID:
26186899
21.

TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.

Kassem L, Deygas M, Fattet L, Lopez J, Goulvent T, Lavergne E, Chabaud S, Carrabin N, Chopin N, Bachelot T, Gillet G, Treilleux I, Rimokh R.

BMC Cancer. 2015 Jun 4;15:453. doi: 10.1186/s12885-015-1471-y.

22.

Inexpensive production of near-native engineered stromas.

Chabaud S, Rousseau A, Marcoux TL, Bolduc S.

J Tissue Eng Regen Med. 2017 May;11(5):1377-1389. doi: 10.1002/term.2036. Epub 2015 May 26.

PMID:
26010652
23.

Organ-specific matrix self-assembled by mesenchymal cells improves the normal urothelial differentiation in vitro.

Bouhout S, Chabaud S, Bolduc S.

World J Urol. 2016 Jan;34(1):121-30. doi: 10.1007/s00345-015-1596-2. Epub 2015 May 26.

PMID:
26008115
24.

Role of JMJD6 in Breast Tumourigenesis.

Poulard C, Rambaud J, Lavergne E, Jacquemetton J, Renoir JM, Trédan O, Chabaud S, Treilleux I, Corbo L, Le Romancer M.

PLoS One. 2015 May 7;10(5):e0126181. doi: 10.1371/journal.pone.0126181. eCollection 2015.

25.

Retroperitoneal nodal metastases from colorectal cancer: Curable metastases with radical retroperitoneal lymphadenectomy in selected patients.

Gagnière J, Dupré A, Chabaud S, Peyrat P, Meeus P, Rivoire M.

Eur J Surg Oncol. 2015 Jun;41(6):731-7. doi: 10.1016/j.ejso.2015.03.229. Epub 2015 Apr 8.

PMID:
25899983
26.

ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.

Trédan O, Ménétrier-Caux C, Ray-Coquard I, Garin G, Cropet C, Verronèse E, Bachelot T, Rebattu P, Heudel PE, Cassier P, Chabaud S, Croughs T, Dupont P, Cadore AC, Clapisson G, Delgado A, Bardin-dit-Courageot C, Rigal C, N'Kodia A, Gilles-Afchain L, Morre M, Pérol D, Blay JY, Caux C.

Ann Oncol. 2015 Jul;26(7):1353-62. doi: 10.1093/annonc/mdv173. Epub 2015 Apr 7.

PMID:
25851629
27.

Behaviour of endothelial cells in a tridimensional in vitro environment.

Ayata RE, Chabaud S, Auger M, Pouliot R.

Biomed Res Int. 2015;2015:630461. doi: 10.1155/2015/630461. Epub 2015 Feb 19.

28.

[The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB].

Ezzalfani M, Dugué A, Mollevi C, Pulido M, Bonnetain F, Filleron T, Gal J, Gauthier M, Le Deley MC, Le Tourneau C, Médioni J, Nguyen JM, Chabaud S, Teixeira L, Thivat E, You B, Kramar A, Paoletti X.

Bull Cancer. 2015 Jan;102(1):73-82. doi: 10.1016/j.bulcan.2014.10.001. Epub 2015 Jan 2. Review. French.

PMID:
25609488
29.

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.

Borget I, Pérol M, Pérol D, Lavolé A, Greillier L, Dô P, Westeel V, Crequit J, Léna H, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Chabaud S, Vergnenegre A, Zalcman G, Chouaïd C; IFCT-GFPC investigators.

BMC Cancer. 2014 Dec 15;14:953. doi: 10.1186/1471-2407-14-953.

30.

Anticancer properties of chitosan on human melanoma are cell line dependent.

Gibot L, Chabaud S, Bouhout S, Bolduc S, Auger FA, Moulin VJ.

Int J Biol Macromol. 2015 Jan;72:370-9. doi: 10.1016/j.ijbiomac.2014.08.033. Epub 2014 Sep 2.

PMID:
25193096
31.

An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents.

Péron J, Polivka V, Chabaud S, Poupart M, Ceruse P, Ramade A, Girodet D, Zrounba P, Fayette J.

BMC Cancer. 2014 Jul 10;14:504. doi: 10.1186/1471-2407-14-504.

32.

The TAILOR study: to agree or to disagree?

Moro-Sibilot D, Perol D, Chabaud S, Cadranel J, Audigier Valette C, Perol M.

Lung Cancer. 2014 Jun;84(3):315-6. doi: 10.1016/j.lungcan.2014.03.019. Epub 2014 Mar 26. No abstract available.

PMID:
24751106
33.

LKB1 when associated with methylatedERα is a marker of bad prognosis in breast cancer.

Bouchekioua-Bouzaghou K, Poulard C, Rambaud J, Lavergne E, Hussein N, Billaud M, Bachelot T, Chabaud S, Mader S, Dayan G, Treilleux I, Corbo L, Le Romancer M.

Int J Cancer. 2014 Sep 15;135(6):1307-18. doi: 10.1002/ijc.28781. Epub 2014 Mar 4.

34.

Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.

Nicolas-Virelizier E, Ségura-Ferlay C, Ghesquières H, Chassagne-Clément C, Gargi T, Biron P, Belhabri A, Rey P, Faurie P, Chabaud S, Sebban C.

Hematol Oncol. 2015 Mar;33(1):1-8. doi: 10.1002/hon.2130. Epub 2014 Feb 5.

PMID:
24496668
35.

Tissue engineering of urinary bladder and urethra: advances from bench to patients.

Orabi H, Bouhout S, Morissette A, Rousseau A, Chabaud S, Bolduc S.

ScientificWorldJournal. 2013 Dec 24;2013:154564. doi: 10.1155/2013/154564. eCollection 2013. Review.

36.

A methodological framework for drug development in rare diseases.

Nony P, Kurbatova P, Bajard A, Malik S, Castellan C, Chabaud S, Volpert V, Eymard N, Kassai B, Cornu C; CRESim; Epi-CRESim.

Orphanet J Rare Dis. 2014 Nov 18;9:164. doi: 10.1186/s13023-014-0164-y.

37.

Design of a randomised controlled trial of adapted physical activity during adjuvant treatment for localised breast cancer: the PASAPAS feasibility study.

Touillaud M, Foucaut AM, Berthouze SE, Reynes E, Kempf-Lépine AS, Carretier J, Pérol D, Guillemaut S, Chabaud S, Bourne-Branchu V, Perrier L, Trédan O, Fervers B, Bachmann P.

BMJ Open. 2013 Oct 28;3(10):e003855. doi: 10.1136/bmjopen-2013-003855.

38.

A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group.

Cassier PA, Lefranc A, Amela EY, Chevreau C, Bui BN, Lecesne A, Ray-Coquard I, Chabaud S, Penel N, Berge Y, Dômont J, Italiano A, Duffaud F, Cadore AC, Polivka V, Blay JY.

Br J Cancer. 2013 Aug 20;109(4):909-14. doi: 10.1038/bjc.2013.442. Epub 2013 Aug 6.

39.

Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients.

Fayette J, Bonnin N, Ferlay C, Lallemant B, Ramade A, Favrel V, Zrounba P, Chabaud S, Pommier P, Poupart M, Céruse P.

Anticancer Drugs. 2013 Jul;24(6):623-9. doi: 10.1097/CAD.0b013e328360b9d6.

PMID:
23542750
40.

Experimental designs for small randomised clinical trials: an algorithm for choice.

Cornu C, Kassai B, Fisch R, Chiron C, Alberti C, Guerrini R, Rosati A, Pons G, Tiddens H, Chabaud S, Caudri D, Ballot C, Kurbatova P, Castellan AC, Bajard A, Nony P; CRESim & Epi-CRESim Project Groups, Aarons L, Bajard A, Ballot C, Bertrand Y, Bretz F, Caudri D, Castellan C, Chabaud S, Cornu C, Dufour F, Dunger-Baldauf C, Dupont JM, Fisch R, Guerrini R, Jullien V, Kassaï B, Nony P, Ogungbenro K, Pérol D, Pons G, Tiddens H, Rosati A, Alberti C, Chiron C, Kurbatova P, Nabbout R.

Orphanet J Rare Dis. 2013 Mar 25;8:48. doi: 10.1186/1750-1172-8-48. Review.

41.

Lysophosphatidic acid enhances collagen deposition and matrix thickening in engineered tissue.

Chabaud S, Marcoux TL, Deschênes-Rompré MP, Rousseau A, Morissette A, Bouhout S, Bernard G, Bolduc S.

J Tissue Eng Regen Med. 2015 Nov;9(11):E65-75. doi: 10.1002/term.1711. Epub 2013 Feb 18.

PMID:
23418181
42.

An endothelialized urothelial cell-seeded tubular graft for urethral replacement.

Imbeault A, Bernard G, Rousseau A, Morissette A, Chabaud S, Bouhout S, Bolduc S.

Can Urol Assoc J. 2013 Jan-Feb;7(1-2):E4-9. doi: 10.5489/cuaj.12217.

43.

Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome.

Trédan O, Manuel M, Clapisson G, Bachelot T, Chabaud S, Bardin-dit-Courageot C, Rigal C, Biota C, Bajard A, Pasqual N, Blay JY, Caux C, Ménétrier-Caux C.

Eur J Cancer. 2013 May;49(7):1673-82. doi: 10.1016/j.ejca.2012.11.028. Epub 2012 Dec 19.

PMID:
23265706
44.

CD4 lymphopenia to identify end-of-life metastatic cancer patients.

Péron J, Cropet C, Tredan O, Bachelot T, Ray-Coquard I, Clapisson G, Chabaud S, Philip I, Borg C, Cassier P, Labidi Galy I, Sebban C, Perol D, Biron P, Caux C, Menetrier-Caux C, Blay JY.

Eur J Cancer. 2013 Mar;49(5):1080-9. doi: 10.1016/j.ejca.2012.11.003. Epub 2012 Dec 13.

PMID:
23246297
45.

High incidence of mammary intraepithelial neoplasia development in Men1-disrupted murine mammary glands.

Seigne C, Auret M, Treilleux I, Bonnavion R, Assade F, Carreira C, Goddard-Léon S, Lavergne E, Chabaud S, Garcia A, Mazoyer S, Lu J, Bachelot T, Frappart L, Zhang CX.

J Pathol. 2013 Mar;229(4):546-58. doi: 10.1002/path.4146.

PMID:
23180448
46.

Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial.

Patrikidou A, Chabaud S, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Domont J, Pérol D, Blay JY, Le Cesne A; French Sarcoma Group.

Ann Oncol. 2013 Apr;24(4):1087-93. doi: 10.1093/annonc/mds587. Epub 2012 Nov 21.

PMID:
23175622
47.

Activation of rapid oestrogen signalling in aggressive human breast cancers.

Poulard C, Treilleux I, Lavergne E, Bouchekioua-Bouzaghou K, Goddard-Léon S, Chabaud S, Trédan O, Corbo L, Le Romancer M.

EMBO Mol Med. 2012 Nov;4(11):1200-13. doi: 10.1002/emmm.201201615. Epub 2012 Oct 15.

48.

A comparative study of patients with and without associated digestive surgery in a two-stage hepatectomy setting.

Stella M, Dupre A, Chabaud S, Gandini A, Meeus P, Peyrat P, Rivoire M.

Langenbecks Arch Surg. 2012 Dec;397(8):1289-96. doi: 10.1007/s00423-012-1002-0. Epub 2012 Sep 29.

PMID:
23053455
49.

ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.

Faget J, Bendriss-Vermare N, Gobert M, Durand I, Olive D, Biota C, Bachelot T, Treilleux I, Goddard-Leon S, Lavergne E, Chabaud S, Blay JY, Caux C, Ménétrier-Caux C.

Cancer Res. 2012 Dec 1;72(23):6130-41. doi: 10.1158/0008-5472.CAN-12-2409. Epub 2012 Oct 1.

50.

Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients.

Manuel M, Tredan O, Bachelot T, Clapisson G, Courtier A, Parmentier G, Rabeony T, Grives A, Perez S, Mouret JF, Perol D, Chabaud S, Ray-Coquard I, Labidi-Galy I, Heudel P, Pierga JY, Caux C, Blay JY, Pasqual N, Ménétrier-Caux C.

Oncoimmunology. 2012 Jul 1;1(4):432-440.

Supplemental Content

Loading ...
Support Center